Drug Trial Radar · NCT00211978
EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)
Last checked: Nov 20, 2026Latest source record: Jan 8, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
May 2005
Primary completion
Jun 2006
Study completion Oct 2006
Sponsor
- Lead sponsor
- Nabi BiopharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.
Conditions
- Hyperphosphatemia
- Kidney Failure
Interventions
calcium acetateDrug
667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
placeboDrug
gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
Primary outcomes
What the sponsor says the trial is designed to measure.
- serum phosphorusTime frame: weeks 5-24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Texas Health Sciences Center
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.